Recombinant cxcl1

RvD2 (MedChemExpress, Shanghai, China) was dissolved in 2% ethanol (vehicle) for i.t. and i.v. injection. Recombinant CXCL1 (Abcam, Cambridge, UK), recombinant IL-17 (ProSpec-Tany TechnoGene Ltd., Rehovot, Israel) and a neutralizing antibody against IL-17 (anti-IL-17, Santa Cruz Biotechnology, Santa Cruz, CA, USA) were dissolved in a vehicle (10% DMSO) for i.t. administration. We selected all the dosages of drugs based on the published literature [18 (link),26 (link),27 (link)]. The intrathecal injection was performed in sevoflurane (induction = 3.0%; maintenance = 1.5%; Maruishi Pharmaceutical Co., Ltd., Osaka, Japan) anesthetized mice, and drugs were administered by a lumbar puncture between the L₄ and L₅ vertebrae through a 30 G needle [28 (link)], while 5 μL of the reagent was delivered following detection of a reflexive tail flick.

A selective CXCR2 antagonist SB225002 (Tocris, Bristol, UK) and recombinant CXCL1 (Abcam, Cambridge, UK) was dissolved in 0.9% normal saline and administration was carried out via intrathecal injection. Deferoxamine (DFO, Sigma-Aldrich, St. Louis, MI, USA) was dissolved in 1% dimethyl sulfoxide (DMSO, Sigma-Aldrich, USA) for intrathecal injection. Under brief anesthesia with sevoflurane, drug injections with 30G needles through intrathecal routes were conducted at the L4-5 spinal segment [23 (link)].